 "DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's")
Dr Reddy’s Laboratories (DRL) is working on several product extensions as well as market expansions for its Covid products portfolio. For example, it is working on bringing in a 1 ml liquid intravenous injectable version of Gilead’s remdesivir, a drug widely used for Covid patients with moderate to severe symptoms.
Similarly, for its oral antiviral drug favipiravir, which it sells under an agreement with Japanese innovator FujiFilm, it is looking to expand markets beyond India, the company said.
As for MSD’s drug Molnupiravir, which is currently undergoing clinical trial in India, the company said it has already shared interim data with the
